September 04, 2025

'No Standard of Care' for GLP-1 Weaning

Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates

KFF Health News

September 03, 2025

FDA Approves Denosumab Biosimilars

The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.

Conexiant

September 02, 2025

OTC Contraception Pill Linked to More Birth Control Starts

Over-the-counter access to progestin-only oral contraceptives shows higher use among patients with prior pregnancies and those not receiving recent contraceptive counseling.

Conexiant

August 20, 2025

USO Tied to Lower HGSC Risk, Study Shows

Researchers assess whether unilateral salpingo-oophorectomy before age 50 lowers cancer risk without raising cardiovascular or bone complications.

Conexiant

August 11, 2025

Why Turning 26 Jeopardizes Health Coverage

A growing number of young Americans lose affordable health insurance at age 26, facing complex Affordable Care Act marketplaces, rising costs, and limited coverage options.

KFF Health News

August 05, 2025

Weight Regain Persists After Anti-Obesity Treatment

A new meta-analysis of 11 randomized controlled trials found that patients began regaining weight as early as 8 weeks after discontinuing anti-obesity medications, with weight gain continuing through 52 weeks.

Conexiant

December 12, 2024

Brief, Vigorous Activity May Lower CV Risk in Women: Study Findings

A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.

Conexiant

November 14, 2024

Can Botox Ease Chronic Pelvic Pain?

A recent study assessed the efficacy of Botulinum Toxin A injections in conjunction with pelvic floor muscle therapy for women with chronic pelvic pain, revealing interesting insights into its effectiveness compared to a placebo.

Conexiant

December 10, 2024

Hormone Therapy Risks Vary: Tibolone Linked to Arterial Events

Recent study links tibolone use in menopausal hormone therapy to a 52% increased cardiovascular disease risk, emphasizing the need for tailored hormone therapy approaches and further research in BMJ.

Conexiant